Fig 1.
Flow diagram depicting the steps of this systematic review.
Table 1.
Characteristics of HBeAg positive chronic hepatitis B patients following 1-year treatment with NAs.
Table 2.
Characteristics of HBeAg positive chronic hepatitis B patients following 2-year treatment with NAs.
Table 3.
Characteristics of HBeAg positive chronic hepatitis B patients following 3-year treatment with NAs.
Table 4.
Characteristics of HBeAg positive chronic hepatitis B patients following 4-year treatment with NAs.
Table 5.
Characteristics of HBeAg positive chronic hepatitis B patients following 5-year treatment with NAs.
Fig 2.
Overview of treatment strategies.
Lines represent direct (head-to-head) comparisons.
Fig 3.
Estimated probabilities for each drug to be ranked for HBeAg seroconversion after 1-year treatment.
Table 6.
Odds ratios of HBeAg seroconversion after 1-year treatment obtained through network meta-analysis.
Fig 4.
Overview of treatment strategies.
Lines represent direct (head-to-head) comparisons.
Fig 5.
Estimated probabilities for each drug to be ranked as HBeAg seroconversion after a 2-year treatment.
Table 7.
Odds ratios of HBeAg seroconversion after 2-year treatment as revealed by network meta-analysis.
Table 8.
Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients.